Related Experiment Video

Updated: Jul 13, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment

Christopher Lischer1, Heiko Bruns2

  • 1Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Cell Reports. Medicine
|October 18, 2023
PubMed

Insights

NEK2 loss reshapes the tumor microenvironment, reducing immunosuppressive cells and T cell exhaustion. This finding enhances the anti-cancer immune response in multiple myeloma.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • The tumor microenvironment (TME) plays a critical role in cancer progression and immune evasion.
  • Understanding the factors that modulate the TME is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the role of NEK2 in modulating the tumor microenvironment in multiple myeloma.
  • To determine the impact of NEK2 loss on immune cell populations and function within the TME.

Main Methods:

  • Utilized genetic manipulation to reduce NEK2 expression in multiple myeloma models.
  • Analyzed changes in immune cell infiltration and phenotype within the tumor microenvironment.
  • Assessed T cell exhaustion markers and anti-cancer immune responses.

Main Results:

  • NEK2 loss led to a significant reduction in tumor-associated macrophages (TAMs).
  • Decreased levels of T cell exhaustion were observed following NEK2 downregulation.
  • The reshaped TME demonstrated an enhanced anti-cancer immune response.

Conclusions:

  • NEK2 is a key regulator of the tumor microenvironment in multiple myeloma.
  • Targeting NEK2 may represent a novel therapeutic strategy to overcome immune suppression in multiple myeloma.
  • Modulating NEK2 can reprogram the TME to favor a potent anti-tumor immune response.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.1K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
170
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
305
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318